We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Common Genetic Marker Predicts Faster Motor Decline in Parkinson’s Disease

By LabMedica International staff writers
Posted on 10 Sep 2026

Parkinson’s disease is a progressive neurodegenerative disorder, but rates of motor decline vary widely among patients, complicating prognosis and clinical trial design. More...

Clinicians have few scalable tools to stratify patients by progression risk early in the disease course. Genetic markers that help identify individuals more likely to worsen quickly could improve trial enrollment and follow-up strategies. A new study shows that common genetic variants are associated with faster motor decline in Parkinson’s disease.

Researchers at the Mass General Brigham Neuroscience Institute (Boston, MA, USA) identified variants in the melanocortin 1 receptor (MC1R) gene as markers of faster motor decline in Parkinson’s disease (PD). MC1R regulates hair and skin pigmentation and also influences cellular responses to oxidative stress in the dopamine-producing neurons affected by PD. Variants that partially reduce MC1R function are common, occurring in more than 60% of patients with PD of European descent.

Using longitudinal data from the international Parkinson’s Progression Markers Initiative (PPMI), with up to 12 years of follow-up, the primary analysis included 383 participants with sporadic PD and compared carriers of MC1R loss-of-function variants with noncarriers. Among patients without a known PD-related mutation, carriers experienced approximately 30% faster motor decline. The association showed an allele dose-response pattern, with two copies of a loss-of-function variant linked to 63% faster decline compared with 27% for one copy.

Findings were replicated in a pooled clinical trial–based cohort of 587 patients, in which carriers had approximately 50% faster motor decline. In a smaller prodromal group not yet clinically diagnosed, carriers were more than four times as likely to develop PD. Together, these data suggest MC1R status may help identify a large subgroup of patients at risk for rapid progression.

The study was published in JAMA Neurology on September 8, 2026. The authors note that these clinical observations, alongside prior preclinical evidence that MC1R agonists can be neuroprotective, support investigating MC1R-based therapeutic strategies in Parkinson’s disease. The work also builds on prior links between MC1R biology, pigmentation, and Parkinson’s disease.

"MC1R variants were common among individuals in our study and associated with substantially faster disease progression," said Xiqun Chen, M.D., Ph.D., senior author and investigator with the Mass General Brigham Neuroscience Institute. "This finding suggests that a simple genetic test could help improve prognostic assessment and clinical trial design for a large proportion of patients. Importantly, MC1R is a druggable target, and drugs that activate this pathway have shown protective effects in preclinical models of PD."

Related Links
Mass General Brigham Neuroscience Institute


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Measuring six variants from one sample may improve research efficiency and support clinical trials of amyloid biology in Alzheimer’s disease and related conditions (Image Credit: Adobe Stock)

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research

Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.